

## FUMITREMORGINS FROM THE MARINE ISOLATE OF THE FUNGUS *Aspergillus fumigatus*


Sh. Sh. Afiyatullof, A. I. Kalinovskii, M. V. Pivkin,  
P. S. Dmitrenok, and T. A. Kuznetsova

UDC 547.94

Marine fungi are a rich source of biologically active compounds of various nature [1, 2]. In continuation of research on secondary metabolites from marine-fungus isolates, we investigated the strain *Aspergillus fumigatus* KMM 4631, which was isolated from a soft coral *Simularia* sp. (Kunashir island, Kuril islands, 52 m deep). It has been demonstrated that this strain produces during cultivation on modified rice medium [3] for 21 days compounds that inhibit the growth of gram-positive bacteria and exhibit cytotoxic activity toward Erlich carcinoma tumor cells.

The cultivation was carried out at 22°C in 20 Ehrlenmeyer flasks (500 mL) containing rice (20 g), yeast extract (20 mg),  $\text{KH}_2\text{PO}_4$  (10 mg), and natural seawater (40 mL).

The mycelium together with the medium was ground and extracted three times with  $\text{CHCl}_3$ :alcohol (2:1). The extract was evaporated. The solid was chromatographed over a column of silica gel L (40/100  $\mu\text{m}$ ) with elution successively by  $\text{CHCl}_3$  and  $\text{CHCl}_3$ :alcohol (10:1 and 5:1). Fractions eluted by  $\text{CHCl}_3$ :alcohol (10:1) were combined, concentrated in vacuum to the minimal volume, and separated by HPLC over Silasorb Si (ethylacetate:hexane, 4:1) and Diaspher-110-C18 (55% MeOH) columns to afford **1** (48 mg), **2** (42 mg), **3** (36 mg), **4** (56 mg), and **5** (40 mg).



**2:**  $\text{R}_1 = \beta\text{-OH}$ ,  $\text{R}_2 = \alpha\text{-OH}$ ; **3:**  $\text{R}_1 = \beta\text{-OH}$ ,  $\text{R}_2 = \alpha\text{-OCH}_3$   
**4:**  $\text{R}_1 = \alpha\text{-OH}$ ,  $\text{R}_2 = \alpha\text{-OH}$ ; **5:**  $\text{R}_1 = \alpha\text{-H}$ ,  $\text{R}_2 = \text{H}$

**Verruculogen (1)**,  $\text{C}_{27}\text{H}_{33}\text{N}_3\text{O}_7$ , mp 232-234°C (MeOH),  $[\alpha]_{\text{D}}^{26} -22.2^\circ$  ( $c$  1.0,  $\text{CHCl}_3$ ),  $R_f$  0.65 (ethylacetate:hexane, 6:1).

Mass spectrum (EI, 70 eV)  $m/z$ : 511 (12)  $[\text{M}]^+$ , 479 (4), 386 (6), 371 (8), 346 (10), 330 (8), 315 (14), 300 (14), 285 (24), 239 (28), 199 (16), 149 (36), 84 (100).

PMR spectrum (300 MHz,  $\text{CDCl}_3$ ,  $\delta$ , ppm, J/Hz): 1.01 (3H, s,  $\text{CH}_3$ -28), 1.72 (3H, s,  $\text{CH}_3$ -29), 1.74 (3H, d,  $J = 1.2$ ,  $\text{CH}_3$ -24), 2.00 (3H, d,  $J = 1.2$ ,  $\text{CH}_3$ -25), 1.65-2.55 (6H, m, H-7, H-8, H-26), 3.63 (2H, t, H-9), 3.82 (3H, s,  $\text{OCH}_3$ ), 4.10 (1H, br.s, OH-12), 4.48 (1H, m, H-6), 4.78 (1H, br.s, OH-13), 5.05 (1H, dm,  $J = 8.0$ , H-22), 5.65 (1H, br.s, H-13), 6.05 (1H, d,  $J = 10.0$ , H-3), 6.59 (1H, d,  $J = 2.2$ , H-19), 6.64 (1H, d,  $J = 8.0$ , H-21), 6.83 (1H, dd,  $J = 2.2, 8.7$ , H-17), 7.90 (1H, d,  $J = 8.7$ , H-16).

Pacific Institute of Bioorganic Chemistry, Far-East Division, Russian Academy of Sciences, 690022, Vladivostok, pr. 100-letiya Vladivostoka, 159, fax 7-(4232) 31 40 50, e-mail: kuzta@piboc.dvo.ru. Translated from *Khimiya Prirodnikh Soedinenii*, No. 6, pp. 506-507, November-December, 2004. Original article submitted September 10, 2004.

<sup>13</sup>C NMR spectrum (75.4 MHz, CDCl<sub>3</sub>): 131.7 (C-2), 49.0 (C-3), 166.3 (C-5), 58.8 (C-6), 29.1 (C-7), 22.7 (C-8), 51.3 (C-9), 170.8 (C-11), 82.6 (C-12), 68.7 (C-13), 105.6 (C-14), 121.1 (C-15), 121.7 (C-16), 109.4 (C-17), 156.5 (C-18), 94.0 (C-19), 136.3 (C-20), 85.9 (C-21), 118.6 (C-22), 143.2 (C-23), 18.8 (C-24), 24.3 (C-25), 45.4 (C-26), 82.2 (C-27), 27.2 (C-28), 25.7 (C-29), 55.8 (CH<sub>3</sub>O-18).

The spectral data of **1** correspond with those in the literature for verruculogen [4, 5].

**Cyclotryprostatin A (2)**, C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>5</sub>, mp 178-182°C (CHCl<sub>3</sub>), [α]<sub>D</sub><sup>26</sup> +83.0° (c 0.4, CHCl<sub>3</sub>), R<sub>f</sub> 0.24.

Mass spectrum (EI, 70 eV) *m/z*: 411 (72) [M]<sup>+</sup>, 243 (66), 200 (100).

PMR spectrum (300 MHz, CDCl<sub>3</sub>, δ, ppm, J/Hz): 7.82 (1H, br.s, NH), 6.65 (1H, d, J = 9.7, H-3), 4.42 (1H, dd, J = 6.0, J = 10.5, H-6), 1.99, 2.49 (2H, m, H-7), 1.99, 2.08 (2H, m, H-8), 3.64-3.80 (2H, m, H-9), 5.10 (1H, s, H-13), 7.45 (1H, d, J = 8.5, H-16), 6.81 (1H, dd, J = 2.2, J = 8.5, H-17), 6.86 (1H, d, J = 2.2, H-19), 5.60 (1H, dm, J = 9.6, H-21), 1.79 (3H, s, CH<sub>3</sub>-23), 2.04 (3H, s, CH<sub>3</sub>-24), 4.43 (1H, br.s, OH-12), 2.20 (1H, br.s, OH-13), 3.82 (3H, s, OCH<sub>3</sub>).

<sup>13</sup>C NMR spectrum (75.4 MHz, CDCl<sub>3</sub>): 133.4 (C-2), 48.9 (C-3), 165.6 (C-5), 60.5 (C-6), 29.9 (C-7), 22.1 (C-8), 45.9 (C-9), 166.9 (C-11), 85.6 (C-12), 68.9 (C-13), 107.5 (C-14), 120.7 (C-15), 118.4 (C-16), 110.0 (C-17), 156.8 (C-18), 95.4 (C-19), 136.8 (C-20), 123.5 (C-21), 138.0 (C-22), 26.0 (C-23), 18.3 (C-24), 55.8 (CH<sub>3</sub>O-18).

**Cyclotryprostatin B (3)**, C<sub>23</sub>H<sub>27</sub>N<sub>3</sub>O<sub>5</sub>, mp 155-160°C (CHCl<sub>3</sub>), [α]<sub>D</sub><sup>26</sup> +108.0° (c 0.2, CHCl<sub>3</sub>), R<sub>f</sub> 0.56.

Mass spectrum (EI, 70 eV) *m/z* (*I*<sub>rel</sub>, %): 425 (59) [M]<sup>+</sup>, 257 (100), 226 (56).

PMR spectrum (300 MHz, CDCl<sub>3</sub>, δ, ppm, J/Hz): 7.90 (1H, br.s, NH), 6.65 (1H, d, J = 9.8, H-3), 4.42 (1H, dd, J = 6.2, J = 10.8, H-6), 2.00, 2.49 (2H, m, H-7), 2.00, 2.10 (2H, m, H-8), 3.70, 3.75 (2H, m, H-9), 4.73 (1H, s, H-13), 7.44 (1H, d, J = 8.5, H-16), 6.82 (1H, dd, J = 2.2, J = 8.5, H-17), 6.88 (1H, d, J = 2.2, H-19), 5.55 (1H, dm, J = 9.7, H-21), 1.79 (3H, d, J = 0.9, CH<sub>3</sub>-23), 2.04 (3H, d, J = 1.3, CH<sub>3</sub>-24), 4.40 (1H, br.s, OH-12), 3.36 (3H, s, CH<sub>3</sub>O-13), 3.82 (3H, s, CH<sub>3</sub>O-18).

<sup>13</sup>C NMR spectrum (75.4 MHz, CDCl<sub>3</sub>): 133.8 (C-2), 49.2 (C-3), 167.1 (C-5), 60.0 (C-6), 29.8 (C-7), 22.2 (C-8), 45.9 (C-9), 166.0 (C-11), 84.8 (C-12), 76.6 (C-13), 105.4 (C-14), 122.7 (C-15), 118.7 (C-16), 110.1 (C-17), 156.5 (C-18), 95.3 (C-19), 136.7 (C-20), 123.7 (C-21), 137.9 (C-22), 26.1 (C-23), 18.3 (C-24), 56.7 (CH<sub>3</sub>O-13), 55.8 (CH<sub>3</sub>O-18).

The spectral data for **2** and **3** correspond with those in the literature for cyclotryprostatis A and B [6].

**12,13-Dihydroxyfunitremorgin C (4)**, C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>5</sub>, mp 196-199°C (MeOH), [α]<sub>D</sub><sup>26</sup> +9.0° (c 0.4, CHCl<sub>3</sub>), R<sub>f</sub> 0.60.

Mass spectrum (EI, 70 eV) *m/z* (*I*<sub>rel</sub>, %): 411 (56) [M]<sup>+</sup>, 394 (13), 371 (4), 330 (4), 315 (8), 257 (44), 243 (100), 226 (36), 214 (30), 200 (86), 187 (42), 159 (16).

PMR spectrum (300 MHz, CDCl<sub>3</sub>, δ, ppm, J/Hz): 7.67 (1H, br.s, NH), 5.87 (1H, dd, J = 1.2, J = 9.5, H-3), 4.42 (1H, dd, J = 6.6, J = 9.1, H-6), 1.99, 2.49 (2H, m, H-7), 1.99, 2.08 (2H, m, H-8), 3.65 (2H, m, H-9), 5.75 (1H, dd, J = 1.3, J = 2.8, H-13), 7.80 (1H, d, J = 8.5, H-16), 6.81 (1H, dd, J = 2.2, J = 8.5, H-17), 6.84 (1H, d, J = 2.2, H-19), 4.79 (1H, dm, J = 9.5, H-21), 1.66 (3H, s, CH<sub>3</sub>-23), 2.01 (3H, s, CH<sub>3</sub>-24), 4.10 (1H, s, OH-12), 4.67 (1H, d, J = 2.8, OH-13), 3.82 (3H, s, CH<sub>3</sub>O-18).

<sup>13</sup>C NMR spectrum (75.4 MHz, CDCl<sub>3</sub>): 130.2 (C-2), 50.2 (C-3), 166.2 (C-5), 58.7 (C-6), 29.2 (C-7), 22.6 (C-8), 45.3 (C-9), 171.0 (C-11), 83.0 (C-12), 68.7 (C-13), 105.5 (C-14), 120.8 (C-15), 121.3 (C-16), 109.9 (C-17), 156.8 (C-18), 95.1 (C-19), 137.6 (C-20), 124.0 (C-21), 134.6 (C-22), 25.7 (C-23), 18.3 (C-24), 55.8 (CH<sub>3</sub>O-18).

The spectral data for **4** correspond with those in the literature for 12,13-dihydroxyfunitremorgin C [7, 8].

**Funitremorgin C (5)**, C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>3</sub>, mp 128-132°C (MeOH), [α]<sub>D</sub><sup>26</sup> -27.0° (c 0.2, CHCl<sub>3</sub>), R<sub>f</sub> 0.40.

Mass spectrum (EI, 70 eV) *m/z* (*I*<sub>rel</sub>, %): 379 (97) [M]<sup>+</sup>, 364 (20), 324 (30), 315 (25), 281 (100), 212 (40).

<sup>13</sup>C NMR spectrum (75.4 MHz, CDCl<sub>3</sub>): 132.2 (C-2), 56.9 (C-3), 165.8 (C-5), 59.3 (C-6), 28.7 (C-7), 23.1 (C-8), 45.5 (C-9), 169.6 (C-11), 51.1 (C-12), 45.5 (C-13), 106.5 (C-14), 120.9 (C-15), 119.0 (C-16), 109.7 (C-17), 156.7 (C-18), 95.4 (C-19), 137.1 (C-20), 124.3 (C-21), 134.1 (C-22), 18.2 (C-23), 25.7 (C-24), 55.9 (CH<sub>3</sub>O-18).

The spectral data for **5** correspond with those in the literature for funitremorgin C [4].

It has been found that **1-5** at concentrations of 10.0-50.0 μg/mL stop division of fertilized egg cells of the sea urchin *Strongylocentrotus intermedius* at the stage of 1-4 blastomers. The most active alkaloid was unhydroxylated funitremorgin C (IC<sub>50</sub> = 10 μg/mL). Compounds **1-5** exhibit cytotoxic activity toward Erlich carcinoma tumor cells *in vitro* (IC<sub>50</sub> = 20-50 μg/mL).

Thus, the marine isolate of *Aspergillus fumigatus* KMM 4631 that was isolated from a soft coral *Sinularia* sp. is a good producer of funitremorgins, potential antitumor preparations [9]. The yields of cyclotryprostatis A and B was three orders of magnitude greater than the previously reported yields of these compounds [7].

## ACKNOWLEDGMENT

The work was supported financially by grants of the Russian Foundation for Basic Research (projects No. 03-04-49528, 02-04-49518), a grant of the RF President No. 1237.2003.4, grant No. 2.2-16 of the Federal Agency for Science and Innovation of the Ministry of Education and Science of the RF, and grant No. 04-1-05-005 of the RAS Presidium "Molecular and Cellular Biology."

## REFERENCES

1. G. N. Belofsky, P. R. Jensen, M. K. Renner, and W. Fenical, *Tetrahedron*, **54**, 1715 (1998).
2. T. S. Bugni and C. M. Ireland, *Nat. Prod. Rep.*, **21**, 143 (2004).
3. Sh. Sh. Afiyatullof, T. A. Kuznetsova, V. V. Isakov, M. V. Pivkin, N. G. Prokof'eva, and G. B. Elyakov, *J. Nat. Prod.*, **63**, 848 (2000).
4. P. S. Stein and R. Vleggaar, in: *Progress of Organic Natural Product*, W. Herz, H. Grisebach, G. W. Kirby, and C. Tamm, eds., Springer-Verlag, New York (1985), Vol. 48, 203.
5. J. Fayos, D. Lokensgard, J. Clardy, R. J. Cole, and J. W. Kirksey, *J. Am. Chem. Soc.*, **96**, 6785 (1974).
6. C.-B. Cui, H. Kakeya, and H. Osada, *Tetrahedron*, **53**, 59 (1997).
7. W.-R. Abraham and H.-A. Arfmann, *Phytochemistry*, **29**, 1025 (1990).
8. S. Kodato, M. Nakagawa, M. Hongu, T. Kawate, and T. Hino, *Tetrahedron*, **44**, 359 (1988).
9. C.-B. Cui, H. Kakeya, G. Okada, R. Onose, and H. Osada, *J. Antibiot.*, **49**, 527 (1996).